email article
The role of genetic testing to guide therapy for patients with metastatic breast cancer is expanding. There are now several mutations with approved indications for treatment, and more are being studied.
But for the clinician, knowing which tests to order for a particular patient can be complicated. Furthermore, with research in this area evolving and new information continually published, interpreting assay results and deciding on the best way to apply them can also be difficult. The two main purposes of genetic profiling are to identify targetable mutations with approved therapies and to identify mutations with matched clinical trial options, Zahi Mitri, MD, of Oregon Health & Science University in Portland, told